Tags : Recordati


Recordati Licenses Exclusive Commercialization Rights of Juxtapid (lomitapide) from Aegerion

Shots: Aegerion (subsidiary of Novelion Therapeutics) to receive $25M upfront, $5M milestones, and royalties on sales of a product. Recordati to get exclusive commercialization rights for Aegerion’s Juxtapid in Japan The focus of the agreement is to develop & commercialize Juxtapid and to strengthen Recordati’s portfolio of rare diseases products in Japan Juxtapid (lomitapide) is […]Read More